title: Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.
authors.affiliation: aExperimental and Clinical Pharmacology Unit bDivision of Medical Oncology A - IRCCS - National Cancer Institute, Aviano (PN), Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Corona
authors.forename: Emanuela
authors.initials: E
authors.lastname: Vaccher
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Toffoli
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004336:Drug Antagonism; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D017320:HIV Protease Inhibitors; D014747:Vinblastine